PATENT COOPERATION TREATMEC'D 0 8 MAR 2005

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

| A 11 II | | 0 27 115 115 11 11 | STittel of International Preliminary | | | | | |
|---|---|------------------------------|--|--|--|--|--|--|
| Applicant's or agent's file reference 490267 SMR/paq | FOR FURTHER See Notification of Transmittal of International Prelimit Examination Report (Form PCT/IPEA/416). | | rt (Form PCT/IPEA/416). | | | | | |
| International Application No. | International Filing Dat (day/month/year) | te . | Priority Date (day/month/year) | | | | | |
| PCT/NZ2003/000232 | 20 October 2003 | | 18 October 2002 . | | | | | |
| International Patent Classification (IPC) or | International Patent Classification (IPC) or national classification and IPC | | | | | | | |
| Int. Cl. 7 A61K 38/01, 38/17, 6/00; A61P 19/08, 1/00 | | | | | | | | |
| Applicant SILCOCK, Patrick Joseph et al | | | | | | | | |
| SILCOCK, Pairick Joseph et al | | | | | | | | |
| | | | | | | | | |
| 1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36. | | | | | | | | |
| 2. This REPORT consists of a total of 4 | sheets, including this o | cover sheet. | | | | | | |
| This report is also accompanied | by ANNEXES, i.e., shee | ets of the description | , claims and/or drawings which have been | | | | | |
| amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). | | | | | | | | |
| These annexes consist of a total | of sheet(s). | | | | | | | |
| 3. This report contains indications relating | ng to the following items: | | | | | | | |
| I X Basis of the report | | | | | | | | |
| II Priority | | | | | | | | |
| III Non-establishment of o | pinion with regard to no | velty, inventive step | and industrial applicability | | | | | |
| IV Lack of unity of invent | ion | • | | | | | | |
| V Reasoned statement un citations and explanation | | | | | | | | |
| VI Gertain documents cite | Gertain documents cited | | | | | | | |
| VII Certain defects in the i | Certain defects in the international application | | | | | | | |
| VIII Certain observations on the international application | | | | | | | | |
| Date of submission of the demand | | Date of completion | of the report | | | | | |
| 4 May 2004 | | 24 February 2005 | | | | | | |
| Name and mailing address of the IPEA/AU | | Authorized Officer | | | | | | |
| AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTR | ALIA | · | | | | | | |
| E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929 | | G.J. McNEICE | | | | | | |
| Facsinine 140. (02) 0263 3727 | | Telephone No. (02) 6283 2055 | | | | | | |





International application No.

PCT/NZ2003/000232

| I. | | f the repo | | | - | | |
|----|---------------------|---|-------------------------------------|---|---|--|--|
| 1. | _ | n regard to the elements of the international application:* | | | | | |
| | X the in | the international application as originally filed. | | | | | |
| | the de | escription, | pages, a | s originally filed, | - | | |
| | | | | led with the demand, | - | | |
| | | | pages , re | eceived on with the letter of | - | | |
| | the c | laims, | pages, as | s originally filed, | | | |
| | • | | pages, as | s amended (together with any statement) under Article 19, | ł | | |
| | | | | led with the demand, | ı | | |
| | | | pages, re | eceived on with the letter of | ١ | | |
| | the d | rawings, | pages , as | s originally filed, | ١ | | |
| | | | pages, fi | iled with the demand, | | | |
| | | | pages, re | eceived on with the letter of | | | |
| | the s | equence lis | sting part of the | e description: | - | | |
| | | | pages , a | as originally filed | 1 | | |
| | | | pages , | filed with the demand | | | |
| | | | pages, 1 | received on with the letter of | | | |
| 2. | which the | internations nents were | al application v available or fu | elements marked above were available or furnished to this Authority in the language in was filed, unless otherwise indicated under this item. Irnished to this Authority in the following language which is: | | | |
| | the l | anguage of | f a translation | furnished for the purposes of international search (under Rule 23.1(b)). | 1 | | |
| | the ! | anguage of | f publication o | f the international application (under Rule 48.3(b)). | | | |
| | | anguage of or 55.3). | f the translatio | n furnished for the purposes of international preliminary examination (under Rules 55.2 | | | |
| 3. | With regar | d to any nu nary exami | ucleotide and nation was car | or amino acid sequence disclosed in the international application, the international ried out on the basis of the sequence listing: | | | |
| | con | tained in th | e international | application in written form. | | | |
| | file | i together v | with the interna | ational application in computer readable form. | | | |
| Ì | furr | ished subs | equently to thi | s Authority in written form. | | | |
| | furr | ished subs | equently to thi | is Authority in computer readable form. | | | |
| | The | statement | that the subsec | quently furnished written sequence listing does not go beyond the disclosure in the iled has been furnished. | | | |
| | The | statement n furnished | that the inform | nation recorded in computer readable form is identical to the written sequence listing has | | | |
| 4. | The | amendme | nts have result | ted in the cancellation of: | • | | |
| | 1 | the de | escription, | pages | • | | |
| | | the cl | laims, | Nos. | • | | |
| | | | rawings, | sheets/fig. | | | |
| 5. | go | beyond the | disclosure as | shed as if (some of) the amendments had not been made, since they have been considered t filed, as indicated in the Supplemental Box (Rule 70.2(c)).** | | | |
| * | Replace report o | ment sheets as "originall | which have bee ly filed" and are | n furnished to the receiving Office in response to an invitation under Article 14 are referred to in the not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). | S | | |
| ** | | | | such amendments must be referred to under item 1 and annexed to this report | | | |





International application No.

PCT/NZ2003/000232

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

| 1. | Statement | · | | |
|----|---------------------------------|--------------|---|-------|
| | Novelty (N) | Claims 44-51 | | YES |
| | | Claims 1-43 | • | NO |
| | Inventive step (IS) | Claims 44-51 | | YES |
| | | Claims 1-43 | | NO |
| | . Industrial applicability (IA) | Claims 1-51 | | YES . |
| | • | Claims | | NO |
| | | | | |

2. Citations and explanations (Rule 70.7)

- D1. O'Sullivan, M.M. "Influence of transglutaminase treatment on some physico-chemical properties of milk" Journal of Dairy Research (2002) 69, pages 433-442 (accepted for publication 20 March 2002)
- D2. Aboumahmoud, R. et al "Crosslinking of Whey Protein by Transglutaminase" J. Dairy Science (1990) 73, p256-263. See pages 257 & 259
- D3. Aoki, T. et al "Caseins are cross-linked through their ester phosphate groups by colloidal calcium phosphate" Biochimica et Biophysica Acta (1987) 911, pages 238-243
- D4. Zhang, Z. P. "Behaviour of Calcium and Phosphate in Artificial Casein Micelles"
 J. Dairy Science (1996) 79, pages 1722-1727
- D5. Aoki, T. "The Least Number of Phosphate Groups for Crosslinking of Casein by Colloidal Calcium Phosphate" J. Dairy Science (1992) 75: pages 971-975. See especially pages 971 and 974.

Novelty (N): Claims 1-51

An hydrolysate of casein is a breakdown product which occurs when casein, a protein found in milk, is broken down by enzymes or acids.

D1 discloses, at page 436, below the figure, milk which is cold renneted to hydrolyse κ -casein followed by addition of Transglutaminase (TGase) to cross-link the casein. At page 438, milk has plasmin added to it to extensively cross-link the β -casein and partially hydrolyse the α_{s1} -casein before partially cross-linking with TGase. Claims 1-38, 42 and 43 are therefore not novel.

Milk is well known to include strontium and fluoride. In relation to Strontium in milk, see, e.g. "Strontium", Retrieved from the internet:<URL:http://www.nei.org/documents/USNRCStrontium.pdf> which states Stable strontium is the 15th most abundant element in nature and it is the most abundant trace element in seawater. Thus, it can become incorporated into all plants and animal tissues. ...The daily intake of strontium varies from about 1.8 to 2.0 mg/day. Of this ... approximately 60 to 90 percent by food.... Strontium is present naturally in many foods.

Intake. ... Milk and milk-byproducts are the major contributors of Sr-90 in western countries. .

In relation to fluoride in milk, see. e.g. R.W. Kahama et al, The Effect of Intrinsic Fluoride in Cows' Milk on in vitro Enamel Demineralization, Caries Research 1998; 32: p200-203 [Retrieved from the internet: <URL:http://content.karger.com/ProdukteDB/produkte.asp?Doi=16453#AC>]

The fluoride concentration in cows' milk has been reported to vary with the fluoride levels in drinking water but it seldom exceeds 0.5 µg/ml The 36% reduction in calcium loss at pH 5.0 by treatment with milk with only 0.3 µg/ml fluoride is an indication that intrinsic milk fluoride has some caries-protective properties.



International application No. PCT/NZ2003/000232

Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of Box V

Milk is therefore known to be a source of strontium and fluoride and, being a common food, is suitable as a mouthwash. Claims 39 to 41 are therefore also not novel.

D2 to D5 disclose crosslinking of casein, but not of an hydrolysate of casein. Claims 1-43 are therefore novel in relation to D2 to D5.

The citations do not disclose or fairly suggest remineralising or treating or preventing dental caries, tooth erosion, dental hypersensitivity or gingivitis (claim 44), nor preparations where the hydrolysis is of 3-8% of the peptide bonds (claims 45-51). Therefore claims 44-51 are novel and involve an inventive step.

Inventive Step (IS): Claims 1-51

As for Novelty

Industrial Applicability (IA): Claims 1-51

Compositions for bioactive metal ion delivery, phosphoprotein preparations and treatments for dental conditions are industrially applicable.